Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
1(50.0%)
Phase 3
1(50.0%)
2Total
Phase 1(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06471959Phase 1Recruiting

Psychedelic-assisted Group Program for First Responders

Role: lead

NCT04523480Phase 3Completed

Testopel ® vs. Generic Testosterone Pellets.

Role: collaborator

NCT04965740Completed

Exploring Medically Perceived Benefits, Use and Interest in Psychedelics and Cannabinoids

Role: lead

All 3 trials loaded